Two orphan leucine-rich repeat-containing G protein-coupled receptors were recently identified as targets for the relaxin family peptides relaxin and insulin-like peptide (INSL) 3. Human gene 2 relaxin is the cognate ligand for relaxin family peptide receptor (RXFP) 1, whereas INSL3 is the ligand for RXFP2. Constitutively active mutants of both receptors when expressed in human embryonic kidney (HEK) 293T cells signal through G␣ s to increase cAMP. However, recent studies using cells that endogenously express the receptors revealed greater complexity: cAMP accumulation after activation of RXFP1 involves a time-dependent biphasic pathway with a delayed phase involving phosphoinositide 3-kinase (PI3K) and protein kinase C (PKC) , whereas the RXFP2 response involves inhibition of adenylate cyclase via pertussis toxin-sensitive G proteins. The aim of this study was to compare and contrast the cAMP signaling pathways used by these two related receptors. In HEK293T cells stably transfected with RXFP1, preliminary studies confirmed the biphasic cAMP response, with an initial G␣ s component and a delayed response involving PI3K and PKC. This delayed pathway was dependent upon G-␤␥ subunits derived from G␣ i3 . An additional inhibitory pathway involving G␣ oB affecting cAMP accumulation was also identified. In HEK293T cells stably transfected with RXFP2, the cAMP response involved G␣ s and was modulated by inhibition mediated by G␣ oB and release of inhibitory G-␤␥ subunits. Thus, initially both RXFP1 and RXFP2 couple to G␣ s and an inhibitory G␣ oB pathway. Differences in cAMP accumulation stem from the ability of RXFP1 to recruit coupling to G␣ i3 , release G-␤␥ subunits and thus activate a delayed PI3K-PKC pathway to further increase cAMP accumulation.
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Relaxin is a two-chain peptide hormone that is structurally closely related to insulin. It belongs to the insulin-relaxin peptide family that includes the relaxins: human gene (H)1 (product of a gene duplication event in higher primates), H2 (major circulating form), and H3 (principally a neuropeptide); insulin; insulin-like growth factors I and II; and the relaxin/insulin-like factors INSL3, INSL4, INSL5, and INSL6. Although relaxin was first identified for its role in parturition in guinea pigs (Hisaw, 1926) , it is now recognized as a hormone with pleiotropic effects. Relaxin has important functions in the heart, kidney, and brain in addition to roles in the regulation of nitric oxide production and neoangiogenesis (for review, see Bathgate et al., 2006) . It is noteworthy that relaxin can also prevent the tissue remodeling observed in fibrosis with a conservation of endogenous tissue structure , and herein lies its potential as a therapeutic.
Despite the length of time since the discovery of relaxin, its receptor remained elusive until the recent pairing of relaxin family peptides with two highly similar leucine-rich repeatcontaining GPCRs: LGR7 and LGR8 . LGR7 was subsequently identified as the relaxin receptor and LGR8 as the receptor for the related peptide INSL3 . More recently, two additional GPCRs were deorphanized using ligands from the insulinrelaxin family: GPCR135 is the receptor for H3 relaxin (Liu et al., 2003) , and GPCR142 is the receptor for INSL5 (Liu et al., 2004) . These four receptors form the relaxin family peptide (RXFP) receptor family, and, based upon recent International Union of Pharmacology recommendations, they are named RXFP1 (LGR7), RXFP2 (LGR8, Great), RXFP3 (GPCR135, SALPR), and RXFP4 (GPCR142, GPR100) (Bathgate et al., 2006) .
Although relaxin mediates many physiological effects, the intracellular signaling pathways involved are still unclear. Despite this, there is evidence for relaxin-mediated activation of a number of signaling pathways, including cAMP. Relaxin has long been shown to increase cAMP levels in numerous target tissues, although the precise mechanism of adenylate cyclase stimulation has not been clearly demonstrated. Studies have shown increases in cAMP in response to relaxin stimulation in THP-1 cells (Parsell et al., 1996) , although this cAMP increase was very weak and required amplification by phosphodiesterase inhibition and adenylate cyclase priming by forskolin. In addition, MAPK inhibitors were shown to decrease cAMP in THP-1 cells, suggesting that MAPK-mediated inhibition of phosphodiesterases is required to give sustained increases in cAMP (Bartsch et al., 2001) . When taken together with little to no cAMP responses in other tissues (Palejwala et al., 1998; Kompa et al., 2002) , this suggested that the involvement of cAMP in relaxin signaling was minimal. However, relaxin stimulation of either RXFP1 or RXFP2 receptors stably expressed in HEK293T cells (HEK-RXFP1 and HEK-RXFP2, respectively) resulted in clear increases in cAMP , and constitutively active mutants showed ligand-independent cAMP production (Hsu et al., 2000 . Thus, unlike previous studies, this clearly demonstrated that RXFP1 and RXFP2 could act as G s -linked GPCRs that signal through adenylate cyclase to increase cAMP.
Recent studies in THP-1 cells (which endogenously express RXFP1) showed a biphasic cAMP response to relaxin stimulation, with an early peak (1-2 min) and a later peak (10 -20 min) that was sensitive to PI3K inhibitors (Nguyen et al., 2003) . Relaxin was subsequently shown to stimulate PI3K, and its effects upon cAMP levels seemed independent of effects on phosphodiesterases (Nguyen et al., 2003) . A general inhibitor of PKC, chelerythrine chloride, also inhibited the later phase of the cAMP response, and relaxin was shown to stimulate the translocation of PKC to the plasma membrane (Nguyen and Dessauer, 2005) . Thus, the relaxin-stimulated cAMP response at RXFP1 is biphasic, and the second phase of the response occurs through a PI3K-PKC-dependent pathway.
Even less is known regarding the signaling events initiated by INSL3 binding to RXFP2. Based upon the identification of RXFP2 as a G s -coupled receptor , signaling studies have thus far focused on cAMP pathways. In HEK-RXFP2 and gubernacular cells (which endogenously express RXFP2), INSL3 stimulation caused increased cAMP levels . In contrast, INSL3 stimulation of testicular germ cells and oocytes caused a decrease in cAMP that was prevented by pretreatment with pertussis toxin (PTX), suggesting that RXFP2 couples to G i /G o proteins (Kawamura et al., 2004) .
Here, we aimed to compare and contrast the cAMP signaling pathways of the RXFP1 and RXFP2 receptors. The study confirms the presence of the delayed PI3K-PKC signaling pathway mediated by RXFP1 in HEK-RXFP1 cells and has identified for the first time that G-␤␥ derived from G␣ i3 is the mediator of this pathway. We have also identified an additional novel cAMP signaling pathway that is part of the immediate response that involves G␣ oB -mediated inhibition of adenylate cyclase. Thus, differences in immediate and delayed cAMP responses are due to involvement of distinct G i /G o isoforms. In HEK-RXFP2 cells, the delayed PI3K-PKC pathway was not involved, showing that RXFP2 is unable to couple to G␣ i3 . Instead, RXFP2 signaling involves a G␣ s stimulation, and we show for the first time involvement of a G␣ oB and G-␤␥-mediated inhibition of cAMP accumulation.
Materials and Methods
Hormones and Reagents. Recombinant H2 relaxin was kindly provided by BAS Medical (San Mateo, CA). Human INSL3 was chemically synthesized by Dr. John Wade (Howard Florey Institute, Melbourne, VIC, Australia). PTX was purchased from Sigma-Aldrich (Sydney, NSW, Australia); LY294002, wortmannin, and bisindolylmalemide I were purchased from Calbiochem (Kilsyth, VIC, Australia); and chelerythrine chloride and PKC pseudosubstrate inhibitor were purchased from BIOMOL Research Laboratories (Plymouth Meeting, PA). The anti-G␣ i/o/t/z antibody was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); biotin molecular weight marker and anti-biotin secondary antibody were both purchased from Cell Signaling Technology, Inc. (Beverly, MA). Donkey anti-goat/sheep secondary HRP-linked antibody was kindly provided by Dr. Grant Drummond (Department of Pharmacology, Monash University, Melbourne, VIC, Australia).
Constructs. ␤-Adrenergic receptor kinase I-C terminus (␤ARK-ct) (Koch et al., 1994) was obtained from Dr. Walter Thomas (Baker Heart Research Institute, Melbourne, VIC, Australia) with the kind permission of Dr. Robert Lefkowitz (Duke University Medical Centre, Durham, NC). The construct produces a segment of the Cterminal end of bovine ␤-adrenergic receptor kinase, which acts to sequester G-␤␥ subunits.
PTX-insensitive G i /G o ␣ subunit mutants were kindly provided by Dr. Patrick M. Sexton (Howard Florey Institute). These G protein ␣ subunits have a Cys351Ile mutation (Bahia et al., 1998) , which renders them insensitive to ADP-ribosylation by PTX.
Cell Culture. HEK293T cells (ATCC CRL-1573; American Type Culture Collection, Manassas, VA) stably expressing either the RXFP1 (HEK-RXFP1) or RXFP2 (HEK-RXFP2) receptors were maintained in RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 2 mM L-glutamine (all from Trace Biosciences, Sydney, NSW, Australia). All tissue culture plates were coated with 0.1 mg/ml poly-L-lysine (Sigma-Aldrich) before use. Cells were maintained at 37°C in a CO 2 water-jacket incubator (Forma Scientific, Marietta, OH) in 5% CO 2 and 85% humidity.
HEK-RXFP1 and HEK-RXFP2 cells were used as described previously (Sudo et al., 2003; Halls et al., 2005b) . Transient transfections were performed using Metafectene (Biontex, Munich, Germany) as per manufacturer's instructions (Halls et al., 2005b) . Cells transiently expressing stated constructs were seeded into 96-well plates 24 h after transfection and used 48 h after transfection.
cAMP Accumulation Assay. cAMP responses were determined using the AlphaScreen cAMP accumulation assay (PerkinElmer, Rowville, VIC, Australia). Cells were seeded into 96-well plates (5 ϫ 10 4 cells/well) in 10% FBS (v/v) RPMI 1640 medium for 8 h and then partially serum-starved overnight [0.5% FBS (v/v) RPMI 1640 medium]. Inhibitors were preincubated with the cells for 30 min in 0.5% FBS (v/v) RPMI 1640 medium, except the myristoylated PKC pseudosubstrate inhibitor and PTX, which were incubated with the cells for 1 and 16 h, respectively. cAMP assays were performed in duplicate as described previously (Halls et al., 2005b) . In brief, cells were incubated with stimulation buffer containing H2 relaxin or INSL3 (concentrations ranging from 0.1 pM to 1 M, as stated), 0.1 mM forskolin (Sigma-Aldrich), or blank for stated time periods at 37°C. After removal of stimulation buffer, cells were frozen in lysis buffer at Ϫ70°C to terminate the Signaling Mechanisms of Relaxin Family Peptide Receptors 215 reaction and to lyse cells. Samples were transferred to a 384-well white Optiplate (PerkinElmer) after thawing, and anti-cAMP acceptor beads then donor beads with biotinylated cAMP were added to all wells.
After overnight incubation, plates were read using a Fusion-␣ microplate reader (PerkinElmer), and the data were analyzed against a standard curve using Prism (GraphPad Software Inc., San Diego, CA). Samples were normalized for cell number by expressing the results as a percentage of the 0.1 mM forskolin response. Each experiment was performed in duplicate, and results are expressed as the mean Ϯ S.E. of the mean of n separate experiments (as stated). All dose-response studies (except 3-min INSL3 stimulation of RXFP2) were best described by a bell-shaped model and were fit to a Gaussian equation. The 3-min INSL3 dose-response curves at RXFP2 were best fit using a GraphPad Prism nonlinear regression sigmoidal dose-response model. Statistical analyses were performed on raw data using a GraphPad Prism unpaired t test, with statistical significance accepted at p Ͻ 0.05.
Western Blotting. HEK-RXFP1 and HEK-RXFP2 cells transiently transfected with PTX-insensitive G␣ i/o (C351I) mutants were lysed and scraped in radioimmunoprecipitation assay buffer (1ϫ phosphate-buffered saline, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, 100 M sodium orthovanadate, and 5 g/ml aprotinin) on ice, collected, and sonicated before addition of 100 g/ml phenylmethylsulfonyl fluoride and centrifugation (10,000g; 10 min; 4°C). Concentration of the protein samples was determined according to Lowry et al. (1951) . Samples were diluted in radioimmunoprecipitation assay buffer to give 1 mg/lane and supplemented with SDS sample buffer (62.5 mM TrisHCl, pH 6.8, 2% SDS, 10% glycerol, 0.1% bromphenol blue, and 10% ␤-mercaptoethanol) at a ratio of 1:1. Proteins were separated on a 10% polyacrylamide gel and electrotransferred to a Hybond-P polyvinylidene difluoride membrane (pore size 0.45 m; GE Healthcare, Little Chalfont, Buckinghamshire, UK) using a semidry electroblotter. After blocking (5% nonfat dry milk and 0.1% Tween 20 in Tris-buffered saline; 1 h at room temperature), the membrane was incubated with primary (anti-G␣ i/o/t/z , 1:500 dilution in Tris-buffered saline with 0.1% Tween 20 and 5% bovine serum albumin; overnight at 4°C) and then secondary (donkey anti-sheep/goat conjugated-HRP and anti-biotin conjugated HRP, both 1:2000 dilution in Tris-buffered saline with 0.1% Tween 20 and 5% nonfat dry milk; 1 h at room temperature) antibodies. Peroxidase activity was observed by chemiluminescence using the Lumi-light Western blotting substrate (Roche Diagnostics, Indianapolis, IN) and exposure to film. (Fig. 1A) . No significant difference in cAMP accumulation was observed in the presence of the PI3K inhibitors at times between 0 and 15 min. Addition of the PI3K inhibitors LY294002 (10 M) or wortmannin (0.1 M) inhibited the second phase (Ͼ15 min) of the response. Conversely, 10 nM INSL3 (Fig. 1B) or 10 nM H2 relaxin stimulation (data not shown) of RXFP2 over a similar period revealed a very different cAMP accumulation profile. There was no effect of the PI3K inhibitors wortmannin (100 nM) or LY294002 (1 M) on either INSL3 or H2 relaxin stimulation at any of the times tested. It is noteworthy that the magnitude of the cAMP response at RXFP2 was significantly smaller than the response obtained by stimulation of RXFP1, despite similar expression levels of both receptors in the cells (Sudo et al., 2003) .
Results

RXFP1, but
In HEK-RXFP1 cells, concentration-response curves were performed measuring cAMP levels at 3 min (pEC 50 ϭ 8.66 Ϯ 0.25) and 30 min (pEC 50 ϭ 9.42 Ϯ 0.22) based upon timecourse data, to further define the characteristics of the responses after stimulation over a short and longer period ( Fig.  2 ; Table 1 ). Two inhibitors of PI3K were used to ensure that the decreases in cAMP were due to specific inhibition of PI3K. LY294002 and wortmannin inhibit PI3K through two distinct mechanisms, thus ensuring PI3K specificity: wortmannin blocks the catalytic subunits of PI3K (Yano et al., 1993) , whereas LY294002 acts at the ATP binding site (Vlahos et al., 1994) . Both 0.1 M wortmannin and 10 M LY294002 significantly decreased the maximum response to 30-min exposure of H2 relaxin by 70 and 60%, respectively ( Fig. 2B ), but they had no effect on the response to a 3-min exposure ( Fig. 2A) . As observed in the time-course studies, the two unrelated PI3K inhibitors had no effect on the concentration-response relationship to INSL3 at RXFP2 after either 3 min (pEC 50 ϭ 8.64 Ϯ 0.44; Fig. 2C ) or 30 min (pEC 50 ϭ 9.24 Ϯ 0.16; Fig. 2D ) exposure to the peptide. The same held true for H2 relaxin stimulation of RXFP2 (data not shown). There was no effect of the PI3K inhibitors on either basal or forskolin-stimulated cAMP levels in either cell line (data not shown) or upon any of the pEC 50 values.
Based upon previous evidence for PI3K activation of PKC to increase cAMP after H2 relaxin stimulation (Nguyen and Dessauer, 2005) , the effect of a general inhibitor of PKC, chelerythrine chloride, was examined ( Fig. 3 ; Table 1 ). Chelerythrine chloride (1 M) significantly inhibited the maximum response to H2 relaxin at RXFP1 at 30 min by 68% ( Fig.  3B ) but had no effect on the response generated at 3 min (Fig.  3A) . The level of inhibition was comparable with that ob- served for wortmannin and LY294002. To confirm involvement of atypical PKC isoforms in this delayed response, a number of PKC inhibitors were used after stimulation with 30 nM H2 relaxin (Fig. 3 , E and F; Table 2 ). Specificity for atypical PKCs ( or /) was thus confirmed using three PKC inhibitors with different activity spectra across the various PKC isoforms: chelerythrine chloride acts as a general PKC inhibitor by acting upon the catalytic domain (Uberall et al., 1997) ; bisindolylmaleimide I is also considered a general inhibitor, although does not have any activity at the atypical isoforms (Martiny-Baron et al., 1993; Uberall et al., 1997) ; and myristoylated PKC is a pseudosubstrate inhibitor that is specific for the atypical PKC isoforms because they exhibit identical sequence within their pseudosubstrate domains (Selbie et al., 1993) . Thus, the overlap in activity of the inhibitors for the various isoforms of PKC allowed confirmation of the specific involvement of an atypical PKC in this system, probably PKC based upon previous studies (Nguyen and Dessauer, 2005) . The specific inhibitor of atypical PKCs, myristoylated PKC pseudosubstrate inhibitor (10 M), significantly inhibited the cAMP response at 30 min by 78% ( Fig. 3F ) but had no effect at 3 min (Fig. 3E) . It is noteworthy that the general inhibitor of PKC that does not inhibit the atypical isoforms, bisindolylmaleimide I (1 M), did not inhibit either the 3-min (Fig. 3E ) or 30-min (Fig. 3F) responses.
As expected, the general PKC inhibitor chelerythrine chloride (1 M) had no effect on the INSL3 concentration-response curve at RXFP2 at either the 3-min (Fig. 3C ) or 30-min (Fig. 3D ) time points. The same was true for the H2 relaxin concentration-response relationship at RXFP2 (data not shown). There was no effect of any of the PKC inhibitors used on basal or forskolin-stimulated cAMP levels in either cell line (data not shown). Chelerythrine chloride did not affect any of the pEC 50 values.
PTX-Sensitive G Proteins Are Involved in Signaling through Both RXFP1 and RXFP2. There is evidence to suggest involvement of PTX-sensitive G proteins in the cAMP accumulation response after stimulation of both 
TABLE 1
Effect of PI3K and PKC inhibitors, PTX pretreatment, and ␤ARK-ct transfection on the maximum RXFP1 and RXFP2 cAMP accumulation responses Effect of 0.1 M wortmannin (30-min preincubation), 10 M LY294002 (30-min preincubation), 1 M chelerythrine chloride (30-min preincubation), 100 ng/ml PTX (16-h preincubation), and ␤ARK-ct transient transfection (114 ng/cm 2 culture area) on the 3-and 30-min maximum responses to H2 relaxin at RXFP1 or INSL3 at RXFP2 is shown. Maximum responses were determined for each separate experiment (performed in duplicate), and then the mean and S.E.M. were determined for each maximum response. cAMP is expressed as a percentage of the 0.1 mM forskolin response at each time point. Results are expressed as mean Ϯ S.E.M. of (n) experiments, each performed in duplicate. (Halls et al., 2005a) and RXFP2 (Kawamura et al., 2004) . Thus, we examined the effect of 100 ng/ml PTX upon time-course and concentration-response relationships at both receptors ( Fig. 4 ; Table 1 ). Preincubation of PTX with HEK-RXFP1 cells revealed different effects upon H2 relaxin stimulation that were timedependent. This was observed in both time-course (Fig. 4A) and concentration-response studies (Fig. 4, C and D) . In time-course studies, from 0 to 20 min there was little effect of PTX pretreatment on cAMP accumulation; however, after 20 min PTX significantly inhibited the RXFP1 response to H2 relaxin (Fig. 4A) . The detailed concentration-response stud- ies confirmed an additional effect of PTX pretreatment: a significantly increased cAMP response by 46% after pretreatment of cells with PTX at the 3-min time point (Fig. 4C ) and a significant inhibition by 37% at the 30-min time point (Fig.  4D) . Thus, PTX-sensitive G proteins seem to mediate distinct pathways leading to cAMP accumulation at early compared with late time points, confirming the biphasic nature of the RXFP1 response.
RXFP1 (H2
It is noteworthy that pretreatment of HEK-RXFP2 cells with PTX increased the INSL3 response at RXFP2 in a consistent manner over a 40-min period (Fig. 4B) . This was also confirmed by concentration-response studies at the two time points, reiterating the monophasic nature of the RXFP2 response. Pretreatment of cells with PTX significantly increased the 3-min response to INSL3 by 43% (Fig. 4E ) and the 30-min maximum response by 48% (Fig. 4F) . PTX pretreatment of HEK-RXFP2 cells had the same effect upon H2 relaxin stimulation (data not shown). Pretreatment of HEK-RXFP2 cells with PTX caused increased basal levels of cAMP. There was no other effect of PTX on basal or forskolin-stimulated cAMP levels in either stable cell line or parent HEK293T cells (data not shown), suggesting some coupling of PTX-sensitive G proteins to RXFP2 at rest. PTX did not affect any pEC 50 values. 
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G-␤␥ Proteins Mediate the cAMP Increases of the Delayed RXFP1 Pathway, but Act to Inhibit cAMP Levels in a Delayed Manner after RXFP2 Stimulation. Because PI3K can be activated by G-␤␥ subunits (Stephens et al., 1994) , we tested the effect of the G-␤␥ scavenger ␤ARK-ct (Koch et al., 1994) on the cAMP responses mediated by RXFP1 and RXFP2 ( Fig. 5; Table 1 ). Cells were transiently transfected with ␤ARK-ct, which sequesters G-␤␥ subunits within cells. The ␤ARK-ct construct expresses a 28-amino acid peptide derived from the ␤ARK-1 protein, which, after activation by G-␤␥ subunits, acts to phosphorylate ␤-adrenoceptors. ␤ARK-ct contains the G-␤␥ binding sequence within ␤ARK1 and would be expected to bind and sequester available G-␤␥ subunits within the cell, inhibiting any resulting signaling pathways. In HEK-RXFP1 cells, as was observed for PI3K and PKC inhibition, ␤ARK-ct transfection significantly decreased the maximum response after a 30-min stimulation by 68% (Fig. 5B ) but had no effect on the immediate cAMP response (Fig. 5A) , suggesting that G-␤␥ subunits mediate the delayed PI3K-PKC pathway.
Again, in direct contrast to RXFP1, ␤ARK-ct-transfected HEK-RXFP2 cells (Fig. 4) resulted in significantly increased cAMP responses after 30-min stimulation, with the maximum increasing by 76% in response to INSL3 (Fig. 5D ). It is noteworthy that this potentiation of the cAMP response was not observed after 3-min exposure to INSL3 (Fig. 5C ). The same effect was observed after H2 relaxin stimulation of RXFP2 (data not shown). This indicates that G-␤␥ subunits used by RXFP2 inhibit cAMP accumulation in a delayed manner. There was no effect of transient expression of ␤ARK-ct on basal or forskolin-stimulated cAMP levels in either stable cells or the parent HEK293T cell line (data not shown), suggesting that all the observed effects are receptormediated. Transient transfection of ␤ARK-ct did not affect pEC 50 values.
The interaction between the various inhibitors, PTX, and ␤ARK-ct was then examined at both RXFP1 and RXFP2 to determine whether the observed effects upon cAMP were due to single or multiple pathways ( Fig. 6; Table 1 ). Concentration-response curves were generated for each condition, with results expressed as the maximum response obtained in each case, because there was no affect of any of the compounds on pEC 50 values. After 3-min stimulation with H2 relaxin in HEK-RXFP1 cells, pretreatment with PTX significantly increased the maximum cAMP response by 46% (Fig. 6A) . Transfection with ␤ARK-ct had no effect, but transfection with ␤ARK-ct and pretreatment with PTX significantly increased the maximum cAMP response by 39%. This suggests that the initial RXFP1 response involves a G s -mediated cAMP accumulation and an inhibition by PTX-sensitive G proteins. There is no involvement of G-␤␥ subunits in the initial cAMP response. At 30-min in HEK-RXFP1 cells (Fig.  6B ), which were pretreated with PTX, the H2 relaxin maximum response was significantly inhibited by 37% compared with the response to H2 relaxin alone. As stated previously, transfection with ␤ARK-ct also significantly decreased the maximum cAMP response, but by 68%. However, transfection of these cells with ␤ARK-ct in addition to PTX pretreatment caused a significant decrease in the maximum cAMP response by only 48%, equivalent to the inhibition caused by pretreatment with PTX alone. Transfection with ␤ARK-ct alone thus caused the greatest degree of inhibition. Because there is no additive inhibitory effect of combined treatment with PTX and ␤ARK-ct transfection, these compounds must inhibit components of the same signaling pathway, thus G-␤␥ subunits must be derived from PTX-sensitive G proteins. However, PTX pretreatment increased the response compared with the effect of ␤ARK-ct alone, suggesting that PTXsensitive G proteins still mediate the inhibitory cAMP pathway at 30 min. The same pattern of behavior was observed for cells pretreated with PTX and wortmannin (Fig. 6E) or for cells pretreated with PTX and chelerythrine chloride (Fig. 6F) . Both wortmannin and chelerythrine chloride alone gave the greatest inhibition of the maximum response, and this was unaltered in cells treated with these inhibitors and also transfected with ␤ARK-ct. However, pretreatment with PTX in addition to wortmannin or chelerythrine chloride exposure increased the maximum response back to the level of response observed after pretreatment with PTX alone. Thus, PTX reverses the effect (or decreases the degree of inhibition) of ␤ARK-ct, wortmannin, or chelerythrine chloride, because it not only removes the stimulatory G-␤␥-PI3K-PKC pathway but also the additional inhibition mediated by PTXsensitive G proteins.
In HEK-RXFP2 cells, pretreatment with PTX caused a 43% increase in the maximum response after 3-min stimulation with INSL3 (Fig. 6C) . Transfection with ␤ARK-ct had no effect on the maximum response; however transfection with ␤ARK-ct in combination with pretreatment with PTX caused an increase in the maximum response by 54%, equivalent to the increase observed with PTX pretreatment alone. Thus, in a manner similar to the initial RXFP1 response, the initial RXFP2 response involves a G s -mediated cAMP accumulation and an inhibition of cAMP by PTX-sensitive G proteins. Pretreatment with PTX also caused an increase in the maximum response to INSL3 stimulation after 30 min at RXFP2, this time by 48% (Fig. 6D) . It is noteworthy that transfection of ␤ARK-ct caused a greater increase in the cAMP response by 76% at this time point. However, there was no difference in the effect of ␤ARK-ct transfection alone compared with the effect of ␤ARK-ct transfection in combination with PTX pretreatment (74%). The same effect was observed after H2 relaxin stimulation of RXFP2 (data not shown). This indicates that G-␤␥ subunits also inhibit cAMP accumulation at 30 min and that they are derived from PTX-sensitive G proteins, because there was no additive effect of pretreatment with PTX in combination with transient transfection of ␤ARK-ct.
The Different cAMP Pathways Activated by RXFP1 and RXFP2 Are Mediated by Different Isoforms of G i / G o . The delayed cAMP signaling pathways activated upon stimulation of RXFP1 and RXFP2 are clearly different and seem to deviate at the level of PTX-sensitive, or G i /G o protein coupling: at RXFP1, PTX pretreatment and ␤ARK-ct transfection act to decrease cAMP levels (i.e., G i /G o -derived G-␤␥ subunits are involved in a stimulatory cAMP pathway), whereas at RXFP2 PTX pretreatment and ␤ARK-ct transfection act to increase cAMP levels (i.e., G i /G o -derived G-␤␥ subunits are involved in an inhibitory cAMP pathway). To address which G proteins were driving the cAMP response, transient transfection of PTX-insensitive G i /G o isoforms was used ( Fig. 7; Table 3 ). The effective interaction of all G protein ␣ subunits with receptors initially requires the exchange of GDP for GTP. In G i /G o , this exchange can be prevented by PTX, rendering the G proteins inactive. G i /G o isoforms are sensitive to ADP-ribosylation by PTX because of a conserved cysteine residue positioned four amino acids Fig. 7 . RXFP1 and RXFP2 both couple to a G␣ oB inhibitory pathway initially, but RXFP1 then recruits G␣ i3 to mediate the delayed G-␤␥-PI3K-PKC stimulatory pathway. All PTX-insensitive G protein isoforms [G␣ i1 (C351I), G␣ i2 (C351I), G␣ i3 (C351I), G␣ oA (C351I), or G␣ oB (C351I); all 114 ng/cm 2 culture area] were expressed after transient expression in both HEK-RXFP1 and HEK-RXFP2 cells as determined by Western blot (A). Bands were observed at the correct molecular mass of approximately 40 kDa. mG␣ denotes PTX-insensitive G protein isoform with Cys 351 Ile mutation. Concentrationresponse curves were performed at 3 min (B and D) or 30 min (C and E) using H2 relaxin (0.1 pM-1 M) at RXFP1 (B and C) or INSL3 (0.1 pM-1 M) at RXFP2 (D and E) in the presence and absence of the G i /G o inhibitor PTX (100 ng/ml; 16-h preincubation) and one of five transiently transfected PTX-insensitive G i /G o ␣-isoforms: G␣ i1 (C351I), G␣ i2 (C351I), G␣ i3 (C351I), G␣ oA (C351I), or G␣ oB (C351I) (all 114 ng/cm 2 culture area). mG␣ denotes PTX-insensitive G protein isoform with Cys 351 Ile mutation. Maximum responses were determined for each separate experiment (performed in duplicate), and then the mean and S.E.M. were determined for each maximum response. cAMP is expressed as a percentage of the 0.1 mM forskolin response at each time point. Bars represent means, and vertical bars represent S.E.M. of the maximum response of four to eight separate experiments performed in duplicate. ‫,ءء‬ p Ͻ 0.01 and ‫,ءءء‬ p Ͻ 0.001 versus the response to peptide alone; *, p Ͻ 0.01 and **, p Ͻ 0.001 versus the response to peptide preincubated with PTX (all maximum responses, unpaired t tests).
from the C terminus. Mutation of this residue therefore causes the isoform to become insensitive to PTX. Transient transfection of one of the G i /G o ␣ (C351I) isoforms (Bahia et al., 1998) and subsequent treatment of cells with PTX (to inactivate endogenous G i /G o isoforms) leaves only the transfected PTX-insensitive G i /G o protein active. Thus, the identity of the G i /G o isoform involved in the cAMP response can be revealed if the isoform transfected restores signaling in the presence of PTX.
There are three isoforms of G␣ i (G␣ i1 , G␣ i2 , and G␣ i3 ) and two forms of G␣ o (G␣ oA and G␣ oB ). Therefore, to determine the isoforms of G i /G o proteins mediating the cAMP response at each receptor, stable cell lines were transiently transfected with PTX-insensitive G i /G o isoforms: G␣ i1 (C351I), G␣ i2 (C351I), G␣ i3 (C351I), G␣ oA (C351I), and G␣ oB (C351I) and treated with PTX ( Fig. 7; Table 3 ). All PTX-insensitive G protein isoforms were expressed after transient transfection in both HEK-RXFP1 and HEK-RXFP2 cells as determined by Western blotting (Fig. 7A) . Faint bands were observed for both HEK-RXFP1, HEK-RXFP2, and the same cells pretreated with PTX. Much stronger bands were observed in cells transiently transfected with the PTX-insensitive G protein isoforms. In HEK-RXFP1 cells stimulated with H2 relaxin for 3 min (Fig. 7B) , only G␣ oB (C351I)-transfected cells restored the cAMP response in the presence of PTX to the level of cAMP stimulated by H2 relaxin alone. The maximum responses of H2 relaxin and G␣ oB (C351I) were significantly decreased compared with PTX-treated cells (36% decrease), whereas transfection of any of the other isoforms [G␣ i1 (C351I), G␣ i2 (C351I), G␣ i3 (C351I), and G␣ oA (C351I)] gave responses that were similar to PTX pretreatment and significantly increased (by a mean of 39, 31, 51, and 35%, respectively) compared with the effect of either H2 relaxin alone or G␣ oB (C351I). Thus, initially RXFP1 can couple to G s , and G␣ oB , which causes inhibition of cAMP. With 30 min of H2 relaxin stimulation (Fig. 7C ), PTX pretreatment with or without G␣ i1 (C351I), G␣ i2 (C351I), G␣ oA (C351I), or G␣ oB (C351I) transfection gave significantly decreased responses (45, 35, 36, 45, and 52%, respectively) compared with the effect of H2 relaxin alone. Transfection with G␣ i3 (C351I) gave a similar response to H2 relaxin alone, and the response was significantly increased compared with the effect of either PTX pretreatment or transfection with G␣ i1 (C351I), G␣ i2 (C351I), G␣ oA (C351I), or G␣ oB (C351I) (by a mean increase of 48%). Thus, at 30-min only G␣ i3 (C351I) restored the cAMP response in the presence of PTX to levels observed in response to H2 relaxin alone. Therefore, RXFP1 couples to G␣ i3 with time, which mediates the G-␤␥-PI3K-PKC pathway.
The effect of transfection of the five PTX-insensitive G i /G o isoforms was then assessed in HEK-RXFP2 cells. After INSL3 stimulation for both 3 min (Fig. 7D ) and 30 min (Fig.  7E) , there was a significant increase in the maximum response to pretreatment with PTX, or transfection with G␣ i1 (C351I), G␣ i2 (C351I), G␣ i3 (C351I), and G␣ oA (C351I) compared with the effect of peptide alone (29, 33, 23, 26, and 26%, respectively) . The response after transfection of G␣ oB (C351I) was not different from the effect of INSL3 alone, but it was significantly decreased compared with the response to either PTX pretreatment or transfection with G␣ i1 (C351I), G␣ i2 (C351I), G␣ i3 (C351I), or G␣ oA (C351I) (by an average of 32%). Thus, only G␣ oB (C351I) transfection in the presence of PTX pretreatment could restore the response to levels observed after INSL3 stimulation alone. This effect did not change with time and was also observed after H2 relaxin stimulation of RXFP2 (data not shown), suggesting that RXFP2 can couple only to G s and inhibitory G␣ oB .
There was no effect of transient transfection of any of the PTX-insensitive G proteins [G␣ i1 (C351I), G␣ i2 (C351I), G␣ i3 (C351I), G␣ oA (C351I), or G␣ oB (C351I)] on basal or forskolin-stimulated cAMP levels in either HEK-RXFP1 or HEK-RXFP2 cells, or in the parent HEK293T cell line (data not shown). None of the PTX-insensitive G protein isoforms had any effect on the pEC 50 values when transiently expressed in HEK-RXFP1 or HEK-RXFP2 cells.
Discussion
The identification of the relaxin receptor (RXFP1) as a GPCR followed by expression in mammalian cells revealed a G s -coupled receptor that when activated increased intracellular levels of cAMP . Although this result is unequivocal, there is a lack of consensus regarding the importance of cAMP as a physiological signaling mechanism in target tissues (Bathgate et al., 2006) . In terms of RXFP2-INSL3 signaling, most studies focus on cAMP, but in different cell types both stimulation and inhibition have been reported Kumagai et al., 2002; Kawamura et al., 2004) . The present study examines cAMP signaling by these receptors in detail, with a specific focus on the G proteins involved.
Recent reports indicate that relaxin activates RXFP1 to cause a biphasic accumulation of cAMP with time (Nguyen et al., 2003; Halls et al., 2005a; Nguyen and Dessauer, 2005) . Initial studies confirmed this finding in HEK-RXFP1 cells. cAMP accumulation was biphasic, and the PI3K inhibitors LY294002 and wortmannin significantly decreased cAMP at the longer time points. These studies enabled the selection of time points at which to construct concentration-response curves: 3 min to capture the immediate phase and 30 min to also capture the delayed phase. Concentration-response studies at these time points confirmed that the delayed pathway has characteristics similar to those identified in THP-1 cells (Nguyen et al., 2003; Nguyen and Dessauer, 2005) , in that the cAMP response is blocked by inhibitors of PI3K and PKC. This suggests that PI3K and PKC are involved only in the delayed phase of cAMP accumulation.
PI3K is often activated by G-␤␥ after receptor stimulation (Stephens et al., 1994) , suggesting that these subunits could be involved in the activation of the delayed pathway in this system. Cotransfection with the G-␤␥ scavenger ␤ARK-ct inhibited the RXFP1 response only at 30 min, to the same degree observed with the PI3K and PKC inhibitors. Thus, the delayed pathway is mediated by G-␤␥ subunits. Timecourse studies also suggested that G-␤␥ subunits were derived from G i /G o proteins, because pretreatment of cells with PTX also blocked the delayed response.
It is noteworthy that, at 3 min, PTX significantly increased the cAMP response compared with H2 relaxin treatment alone. This indicated that the receptor also couples to an inhibitory G i /G o pathway. This pathway also contributes to the overall cAMP response at 30 min, suggesting the existence of three pathways: a G s -mediated stimulation of cAMP (H2 relaxin in the presence of PTX), a G i /G o -mediated inhibition (shown by the significant difference in response between PTX-treated and ␤ARK-ct-treated cells), and a G i /G oderived G-␤␥-mediated delayed cAMP increase via PI3K and PKC (as demonstrated by effect of ␤ARK-ct, wortmannin, or chelerythrine chloride alone). Use of PTX-resistant G i /G o mutants revealed differential G i /G o coupling with time, providing further evidence for the activation of three pathways. The only isoform to restore signaling at 3 min to the characteristics of the wild-type was G␣ oB (C351I). This suggested that RXFP1 couples to G␣ oB initially to inhibit adenylate cyclase and decrease cAMP. However, at 30 min the only isoform that restored signaling in the presence of PTX was G␣ i3 (C351I). Thus, RXFP1 seems to initially couple to G␣ s and G␣ oB (Fig. 8A ) but then recruits G␣ i3 to release G-␤␥ subunits that activate the delayed PI3K-PKC pathway (Fig. 8B) .
The involvement of G i /G o proteins in the RXFP1 response to relaxin has been reported previously (Kompa et al., 2002) . In functional assays, PTX pretreatment significantly decreased the maximum inotropic and chronotropic responses to relaxin in rat isolated atria, without alteration of potency. PTX pretreatment also significantly decreased cAMP in the same tissue. Thus, it seems that the model of cAMP accumulation presented here also exists at a physiological level. We suggest therefore that differences in relaxin-mediated signaling observed across a variety of cell types can be explained by the differential expression patterns of G s , G␣ oB , and G␣ i3 , and thus by differential emphasis placed upon the three signaling pathways.
The mechanism of the recruitment of G␣ i3 by RXFP1 is as yet unclear. The delay may potentially reflect the time required for translocation of PKC to the cell membrane. In rat-1 fibroblasts expressing ␣ 1A adrenoceptors, stimulation with phenylephrine caused significantly increased levels of PKC in particulate fractions after 15 min (Parmentier et al., 2004) . Relaxin-mediated PKC translocation has been shown to occur as early as 2 min in PHMI-31 and THP-1 cells (Nguyen and Dessauer, 2005) , and by 10 min in cells isolated Fig. 8 . cAMP signaling pathways activated by stimulation of RXFP1 and RXFP2. Binding of H2 relaxin to RXFP1 initially results in coupling to G s to activate adenylate cyclase and increase cAMP and also to G␣ oB to inhibit adenylate cyclase and decrease cAMP accumulation (A). After a period of approximately 5 to 20 min, RXFP1 can recruit G␣ i3 (B). The release of G-␤␥ from G␣ i3 allows the activation of PI3K and activation and translocation of PKC to further stimulate adenylate cyclase and cAMP production. Activation of RXFP2 by either INSL3 or H2 relaxin involves only the stimulation of adenylate cyclase to increase cAMP via G s , and the inhibition of cAMP production through adenylate cyclase by G␣ oB (C) and derived G-␤␥ subunits with time (D). Lines with arrows represent cAMP stimulatory pathways, those with circles, inhibitory pathways, and dotted lines, delayed pathways. Components of the immediate response at each receptor are unshaded, whereas components of the delayed response are shaded.
